Skip to main content

Selecting and Prescribing a Biosimilar

Before starting each module, please take a moment to submit your college information here. MIMS will collect the data of the participation to corresponding colleges. Also please check that your account is updated with your current professional details (including your registered medical license number), as these details will be printed in your course completion certificate.

If you have any enquiries, please contact MIMS via or call +852 2559 5888.

The information contained on this site is intended for Healthcare Professionals only

The materials in this virtual exhibition are approved for use only in Hong Kong. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/ or the Summary of Product Characteristics (SmPC).

About this course

Module 3 of Biosimilar Modules for Continued Professional Development comprises three videos. Dr Gunar Stemer of Vienna General Hospital, Austria, Professor Irene Krämer of Medical Center of the Johannes Gutenberg-University, Mainz, Germany, Dr Niels Boone of Zuyderland Medisch Centrum, Maastricht, The Netherlands, Julien Taïeb of Université Paris Descartes, France, Dirk Arnold of Asklepios Tumorzentrun Hamburg, Germany, and Simon Cheesman of University College London Hospitals, United Kingdom discuss what pharmacists need to consider when prescribing a biosimilar, the importance of educating all stakeholders with regards to biosimilar agents and challenges of biosimilars’ pharmacovigilance.

Topics covered

  • What pharmacists should consider when prescribing a biosimilar
  • Reliability of supply
  • Drug-related selection criteria
  • Patient-related selection criteria
  • Inter-batch variability of biologics and biosimilars
  • Challenges in extrapolating efficacy and risks between populations
  • Post-marketing surveillance
  • List of criteria necessary for European Medicines Agency approval
  • Selection matrix tool
  • Challenges in biosimilar selection and use
  • Pharmacovigilance
  • Education of physicians, pharmacists, nurses and patients on biosimilars

Learning outcomes

  • Considerations when prescribing a biosimilar
  • Appreciating the role of hospital pharmacists when selecting a biosimilar
  • Acceptance of variability of biologics and biosimilars
  • Understanding the differences in originator and biosimilars assessment
  • Learning about a selection matrix tool for biosimilars
  • Appreciating the importance of pharmacovigilance
  • Understanding the importance of educating physicians, pharmacists, nurses and patients on biosimilars

CME Accreditors#:

Hong Kong College of Community Medicine (AP-SS)
Hong Kong College of Radiologists (B-PP)
The College of Surgeons of Hong Kong (CME-PP)

#Please contact respective authorities directly for CME accreditation if it is not listed above

0.5 CME points available

  • A minimum score of 8/10 (80%) in the multiple-choice quiz is required to obtain 0.5 CME points.
  • A certificate can be downloaded upon successful completion.

Sponsored by

Organised by